AMOEBA :2016 full-year results in line with development

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
43
AMOEBA :2016 full-year results in line with development plan

press release

2016 full-year results in line with development plan

Chassieu, 22nd March 2017 - AMOEBA (FR0011051598 - AMEBA), manufacturer of a biological biocide capable of eliminating waterborne bacterial risk, announced today its 2016 full-year results.

At the meeting held on 20th March 2017, the Executive Board of Directors closed the annual and consolidated accounts of AMOEBA Group for the year ending 31 st December 2016. The accounts were examined by the Supervisory Board at the meeting held on 22 nd March 2017. The auditors performed their audit work and nothing came to their attention that could raise doubt as to the conformity of the accounts.

(In K€) 31/12/2016 31/12/2015
Turnover 126 141
Industrial deployment (652)  
R&D costs (2 640) (1 485)
Subsidies 576 449
Marketing & Sales (1 073) (647)
General costs (2 090) (2 446)
Operational balance (5 753) (3 988)
Before-tax balance (5 768) (4 019)
Net balance (5 768) (4 019)

Annual results in line with expectations

The turnover on 31st December 2016 was €126K, mainly made up of the license fee of €120 K paid by AQUAPROX.

The expenditure for industrial deployment consist of staff costs and purchases of consumables for the implementation of production projects and the improvement of technical processes.

The R&D costs are linked to the development of the biocide in an industrial environment. The subsidies correspond solely to the research tax credit.

The marketing and sales costs consist of personnel costs and travel costs linked to the set-up of the commercial network.

The sharp drop in general costs compared to 2015 is due to the transfer of some of these costs to the industrial deployment project. They mainly consist of salaries for support staff and fees.

Consequently, the operational balance is - €5 753K and the net balance is - €5 768 K.

A solid financial structure

As of 31st December 2016, the company's equity was €18.6M compared to €10.6M on 31st December 2015. Since the last account closure, the Company increased its capital by a total amount of € 14.7M (issue premium included and excluding commissions and fees), by private European and American investors. Financial debts amount to € 3M compared to € 1.9M in 2015. This increase mainly corresponds to credit financing for the first line of production at Lyon-Chassieu. As of 31 st December 2016, the cash flow was € 7.7M.

2016 saw the signature of new distribution agreements, the marketing authorization to start industrial R&D tests in Europe and the set-up of a pilot production site in Canada.

In the course of 2016, AMOEBA signed new letters of intention with the following companies to distribute its product overseas, subject to the required marketing authorization (MA) being granted in each respective country:

      -          AQUACONCEPT POLSKA for Poland in January 2016;       -          GREEN CHEMICALS for Turkey in March 2016 and Brazil in September 2016;       -          AQUA-SERV for 3 states in the USA in September 2016; and       -          OXIDINE for Spain in December 2016.

In addition, AMOEBA was granted authorization to carry out industrial tests in Belgium (February 2016), in Italy (April 2016), in Spain and in Germany (September 2016). 

Finally, the Company has set up a new pilot production site in Montreal (Canada) able to produce the required biocide for industrial tests on the North American continent.

Continuing with the dynamics in 2017

During the first quarter of 2017, AMOEBA has signed three new letters of intent to distribute its products with Garratt Callahan and Kroff in the USA, and NCR in Italy.

The Company is also reviewing the possibility to start R&D tests in the USA from the second quarter of 2017.

Following the evaluation report from the French competent authority, ANSES, AMOEBA is expecting to receive a decision from Europe at the end of 2017 before starting the commercialization of its product. AMOEBA considers to have sufficient funds to carry out its R&D field tests in Europe and North America, and to carry out research and development work on new applications.

Next meetings: General Assembly for shareholders: 22nd June 2017 About AMOEBA: AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn (1) , AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn (2) . AMOEBA is continuing with the regulatory procedures necessary to obtain MA for all European countries for the "Air Cooled Towers" application. Based in Lyon-Chassieu (France), AMOEBA is quoted on compartment B of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.

(1) : Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets (2) : Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts  :

Amoéba Nathalie COMBROUSSE Responsable Marketing Communication +33 (0)4 81 09 18 15 nathalie.combrousse@amoena-biocide.com Actifin Ghislaine GASPARETTO Communication financière +33 (0)1 56 88 11 11 ggasparetto@actifin.fr
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...810c8b6bf3

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 93

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 51

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 45

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 43

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 76

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Alfa Laval Enhances Gulf Coast Support with La Porte Expansion

Updated Category News Views 183

Alfa Laval Strengthens Local Support with La Porte Service Center Alfa Laval, a world leader in heat transfer, separation, and fluid handling, is proud to announce the expansion of its Service Center in La Porte, Texas. This newly expanded facility is set to bolster the support for the Gulf Coast's industrial community, demonstrating the company’s commitment to local...

Continue Reading
AgEagle Aerial Systems Achieves Impressive Q1 Financial Gains

Updated Category News Views 209

AgEagle Aerial Systems Achieves Strong Financial Results A remarkable transformation is underway at AgEagle Aerial Systems Inc. (NYSE: UAVS), a key player in unmanned aerial systems (UAS) and sensor technology. The company has announced financial results for the first quarter of fiscal year 2025, showcasing a sharp recovery and robust performance in various financial...

Continue Reading
Empowering Future Leaders: The 6th Student Research Competition

Updated Category News Views 259

Empowering Future Leaders: The 6th Student Research Competition The Fixed Income Analysts Society (FIASI), in partnership with Fordham University's Center for Research in Contemporary Finance and the O'Shea Center for Credit Analysis and Investment, is excited to announce the launch of its highly anticipated 6th Annual FIASI – Gabelli School Student Research...

Continue Reading
LALO Tequila Unveils Unique 2025 High Proof Blanco Expression

Updated Category News Views 414

Introducing the 2025 High Proof Blanco Tequila LALO Tequila proudly presents its latest creation, the 2025 High Proof Blanco, marking a significant chapter in its celebrated line of limited-edition spirits. Scheduled just in time for Hispanic Heritage Month, this release embodies the brand’s strong cultural roots while embracing modern advancements in the tequila...

Continue Reading
TaskUs, Inc. to Reveal Q3 2024 Earnings on November 7

Updated Category News Views 95

TaskUs, Inc. to Reveal Financial Results for Q3 2024 TaskUs, Inc. (Nasdaq: TASK), a prominent leader in providing outsourced digital services and advanced customer experience, will disclose its third quarter 2024 financial results following the market's closure on November 7. Conference Call and Webcast Details Management will conduct a conference call and webcast at 5:00...

Continue Reading